)
)
Edge16 Oct 2026
Winner, Winner: The Chicken McNugget Story
How a 1940s breeding contest, a Cornell food scientist, and a hedge by Ray Dalio helped McDonald's turn the Chicken McNugget into a fast-food icon.
Crinetics Pharmaceuticals
Crinetics Pharmaceuticals (CRNX) investor relations material
Crinetics Pharmaceuticals Q2 2026 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Q2 2026 earnings summary3 Aug, 2026
Executive summary
Entered into a definitive merger agreement with Vertex Pharmaceuticals for $10.0 billion ($8.8B net of estimated cash acquired), at $85.00 per share in cash, with the deal expected to close in Q3 2026 pending regulatory and shareholder approval.
Continued strong commercial uptake of PALSONIFY, with 245 new patient enrollment forms, 385 unique prescribers, and net product revenue of $24.0 million in Q2 2026.
Expanded regulatory approvals for PALSONIFY in the EU and ongoing submissions in Brazil and Japan.
Advanced pipeline with atumelnant and other candidates; initiated new clinical studies and received FDA Rare Pediatric Disease Designation for atumelnant.
Financial highlights
Q2 2026 total revenue was $25.1 million, up from $1.0 million in Q2 2025, driven by PALSONIFY product sales.
Net loss for Q2 2026 was $120.9 million, compared to $115.6 million in Q2 2025.
Operating expenses increased to $157.6 million in Q2 2026, with R&D at $99.9 million and SG&A at $57.6 million.
Cash, cash equivalents, and investment securities totaled $1.2 billion as of June 30, 2026.
Completed a $380 million public equity offering in January 2026.
Outlook and guidance
With the pending Vertex acquisition, all previously issued guidance has been withdrawn and no updated guidance is provided.
Sufficient liquidity to fund operations for at least the next 12 months.
Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.Research faster. Power your platform.
Latest events from Crinetics Pharmaceuticals
- Shareholders will vote on a cash merger with Vertex at $85.00 per share, with board support.CRNX
Proxy filing - Pipeline advances in acromegaly, CAH, and NETs, with strong financial runway into 2030.CRNXCorporate presentation
- Shareholders to vote on $85/share cash merger with Vertex, with board unanimous support and appraisal rights.CRNXProxy filing
- Merger agreement signed with Vertex; key executives enter non-competes and shareholders to vote.CRNXProxy filing
- PALSONIFY launch drives strong early results; $1.1B cash supports pipeline into 2029.CRNXQ3 2025
- Advancing novel endocrine and oncology therapies with late-stage programs and strong financials.CRNXR&D Day 2025
- Multiple late-stage programs and commercial readiness signal strong growth into 2025 and beyond.CRNXPiper Sandler 36th Annual Healthcare Conference
- NDA for paltusotine submitted; $1.4B cash funds pipeline and late-stage trials into 2029.CRNXQ3 2024
- Q2 2024 saw strong pipeline progress, higher expenses, and $863M in cash for future growth.CRNXQ2 2024
Next Crinetics Pharmaceuticals earnings date
Q3 202619 Nov, 2026
Crinetics Pharmaceuticals
Next Crinetics Pharmaceuticals earnings date
Q3 202619 Nov, 2026
AI chat
Ask anything. Verify everything.
Ask across every event and document from public companies. Each answer links back to the exact line in the transcript, slide or filing it came from.Learn moreFind what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.)
Trust every finding
50m+ first-party documents. Every output traceable to its source.Find what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.Trust every finding
50m+ first-party documents. Every output traceable to its source.Automations
Zero in on what matters
Define the prompt once. It runs the moment a company publishes or on a schedule you set. Outputs map to the exact signals you choose.Learn more)
Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.)
Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Live audio & transcripts
Be first
Join any earnings call live in one click, with no manual registration. Follow the transcript as it happens and jump straight to the moments that matter.Learn more)
Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.)
Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Quartr MCP connects your AI environment to 17K+ public companies
Pull live transcripts, filings, and slides into Claude or Codex via MCP. Combine Quartr's global IR data with any other dataset. Run agentic research and monitoring.
Included with Quartr Pro at no extra cost.Learn more
Quartr's AI stands out because it only pulls clean, first-party data from public companies. In investing, that's everything.
Jamie Ross
Investment Manager, GAM Investments
GAM
GAM
Research that used to take hours now takes seconds with Quartr Pro. Tracking shifts in tone or extracting tables, it's as simple as typing a query.
Tom O'Hara
Investment Director
Ciena
Ciena
Before Quartr we spent hours manually compiling insights through the peer earnings cycle. Now, these tasks are done faster, with greater precision.
Gregg Lampf
VP of Investor Relations
Protean
Protean
Being able to ask specific questions across years of transcripts and reports and instantly get verified answers is a game-changer.
Pontus Dackmo
CEO & Investment Manager
)
)
Frequently asked questions
Crinetics Pharmaceuticals Inc. is a clinical-stage pharmaceutical company that specializes in the development of novel therapeutics targeting peptide hormone receptors. Their focus is on the treatment of rare endocrine disorders and endocrine-related tumors. The company’s leading product candidate is Paltusotine, an oral selective nonpeptide somatostatin receptor type 2 agonist. It is in advanced clinical trials for conditions such as acromegaly, carcinoid syndrome, and nonfunctional neuroendocrine tumors. Additionally, Crinetics Pharmaceuticals is developing other drug candidates for conditions like congenital hyperinsulinism and Cushing's disease. The company is headquartered in San Diego, California, and its shares are listed on the NASDAQ.